SciELO - Scientific Electronic Library Online

 
vol.30 número3Administración intratecal en dosis mínima de morfina para el manejo del dolor postquirúrgico en cesáreaEstridor post-extubación en el paciente pediátrico índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay artículos similaresSimilares en SciELO

Compartir


Anestesia en México

versión On-line ISSN 2448-8771versión impresa ISSN 1405-0056

Resumen

BARRAZA-ZETINA, A; OBREGON-CORONA, A  y  MUNOZ-GARCIA, A. Evaluation of renal function after administration of fluorescein in neurosurgery. Anest. Méx. [online]. 2018, vol.30, n.3, pp.47-54. ISSN 2448-8771.

Surgery guided by fluorescein sodium (FLS-Na), is a technical standard neurosurgical, which includes intravenous administration of this compound, in damaged areas of the barrier (BHE) blood-brain of the tumor areas and if allows the tissue differences neoplastic healthy brain tissue to its proper resection. The main complication associated with the administration of fluorescein is nephropathy induced by contrast, which is defined as 25% of the values of serum creatinine increase. Renal failure, after the application of intravenous fluorescein, has not been evaluated in neurosurgery.

Objective:

Evaluate kidney function after the application of intravenous FLS-Na in neurosurgical patients.

Material and methods:

retrospective, observational, cross-sectional study. Review of 40 records of patients undergoing neurosurgery, guided by FLS-Na at the National Institute of Neurology and Neurosurgery (INNN), baseline, type of intervention including demographic, clinical and laboratory characteristics studied surgical. Baseline values and post-surgical of serum creatinine, uremia and rate glomerular to evaluate renal function. Results: 37 records were included, three were excluded. They were classified by the TGF. 9 patients were classified as normal > 90, 26 patients (70%), stage II (60-89) (24.3%), stage III (30-59), one patient (2.7). Stadium IV (16-30) one patient (2.7%). Patients did not show significant changes in the increase of serum creatinine back to intravenous application of fluorescein in relation to its TGF respectively.

Palabras llave : Fluorescein; renal function; arteriovenous malformations; skull base tumors; gliomas.

        · resumen en Español     · texto en Español     · Español ( pdf )